The WHO informed the WSO that alteplase is now included in the 21st EML. Used in specialised diagnostic or monitoring facilities, and with specialist medical care, as described in the WSO’s Road Map for Quality Stroke Care.

This new treatment options are likely to have an important impact on stroke incidence, and long-term outcome worldwide. As a result, especially in combination with health policy, organised stroke care systems, and lifestyle changes.